Published in Medicine and Law Weekly, December 10th, 2004
The license is for research use only.
"We are pleased to have gained access to important parts of Affymetrix' patent portfolio in this area," said Dr. Frank Witney, president and CEO of Genospectra. "Affymetrix's work in this field may be synergistic with QuantiGene and QuantiGene-Plex, our proprietary signal amplification products that offer robust and precise RNA quantification directly from cell lysates or tissue homogenates."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly